SG/CALL/BRISTOL-MYERS SQUIBB/90/0.1/20.09.24 | Delayed Deutsche Boerse AG 02:51:54 2024-05-22 am EDT | ||
| 0.001 EUR | 0.00% |
|
| Current year | -50.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-05-22 | 0.001 | 0.00% |
| 24-05-21 | 0.001 | 0.00% |
| 24-05-20 | 0.001 | 0.00% |
| 24-05-17 | 0.001 | 0.00% |
| 24-05-16 | 0.001 | 0.00% |
Delayed Quote Deutsche Boerse AG
Last update May 22, 2024 at 02:51 am EDT
More quotesStatic data
| Product type | Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
Société Générale
|
| WKN | SQ8Z6Q |
| ISIN | DE000SQ8Z6Q8 |
| Date issued | 2023-02-13 |
| Strike | 90 $ |
| Maturity | 2024-09-20 (122 Days) |
| Parity | 10 : 1 |
| Emission price | 0.31 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.35 € |
|---|---|
| Lowest since issue | 0.001 € |
| Delta | 0x |
| Omega | 0.000000 |
| Premium | 0x |
| Gearing | 0x |
| Moneyness | 0.4697 |
| Difference Strike | 47.73 $ |
| Difference Strike % | +53.03% |
| Intrinsic value | 0.000000 |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
42.27
USD
Average target price
53.19
USD
Spread / Average Target
+25.84%
- Stock Market
- Warrants
- Warrant